Healthy Lifestyle

Low-dose Gout Drug, Colchicine, Has Been Approved to Reduce Cardiovascular Events in Patients with Coronary Disease

Pendopharm, a division of Pharmascience Inc., has announced an existing anti-inflammatory gout drug as a new repurposed treatment.

In August 2021, Health Canada issued a Notice of Compliance (NOC) approving Myinfla ER (colchicine 0.5 mg extended-release tablets), a prescription medication for use in the reduction of cardiovascular risks in patients with coronary artery disease.

The approval was primarily based on the results of the Colchicine Cardiovascular Outcomes Trial (COLCOT) led by Dr. Jean-Claude Tardif from the Montreal Heart Institute, in partnership with Pharmascience.

Published in the prestigious New England Journal of Medicine, the results demonstrated that the treatment with low-dose colchicine (0.5 mg) reduces the risk of a first ischemic cardiovascular event by 23% and the risk of overall ischemic events by 34% in patients having suffered a myocardial infarction (Tardif et al., N Engl J Med 2019; 381:2497-505).

Myinfla ER 0.5 mg (colchicine extended-release tablets) is now available in For any inquiries, please contact Customer Service at: 1-844-4CHEAPO (424-3276). (Monday – Friday, 8:00 AM to 8:00 PM CST | Saturday – Sunday, 8:00 AM to 4:00 PM CST).



If you have questions about your prescription medications or any other medication, please contact our team at CheapoMeds by calling toll free 1-844-4CHEAPO (424-3276). One of our patient representatives will be happy to assist you or transfer you to a licensed Canadian pharmacist for a free consultation.

This article contains medical information provided to help you better understand this medical condition or process and may contain information about medication often used as part of a treatment plan prescribed by a doctor.  It is not intended to be used as either a diagnosis or recommendation for treatment of your medical situation.  If you are unwell, concerned about your physical or mental state, or are experiencing symptoms you should speak with your doctor or primary health care provider. If you are in medical distress, please contact emergency services (such as 911).

One comment on “Low-dose Gout Drug, Colchicine, Has Been Approved to Reduce Cardiovascular Events in Patients with Coronary Disease

Leave a Reply

Your email address will not be published. Required fields are marked *